# A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

> **NCT06679829** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 215 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Siltuximab
- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT06679829
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-06
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 215 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06679829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06679829, "A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06679829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*